Formulation and optimization of a single-layer coat for targeting budesonide pellets to the descending Colon

References

• Akhgari A, Garekani HA, Sadeghi F, Azimaie M. 2005. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm. 305(1-2):22–30. doi: 10.1016/j.ijpharm.2005.08.025.
   PubMed Web of Science ®Google Scholar
• Ali H, Weigmann B, Collnot E-M, Khan SA, Windbergs M, Lehr C-M. 2016. Budesonide-loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa—pharmaceutical characterization and fluorescence imaging. Pharm Res. 33(5):1085–1092. doi: 10.1007/s11095-015-1852-6.
   PubMed Web of Science ®Google Scholar
• Antony J. 2014. 6 - Full Factorial Designs. Design of Experiments for Engineers and Scientists. 2:63–85.
   Google Scholar
• Asadi M, Salehi Z, Akrami M, Hosseinpour M, Jockenhövel S, Ghazanfari S. 2023. 3D printed pH-responsive tablets containing N-acetylglucosamine-loaded methylcellulose hydrogel for colon drug delivery applications. Int J Pharm. 645:123366. doi: 10.1016/j.ijpharm.2023.123366.
   PubMedGoogle Scholar
• Bassotti G, Antonelli E, Villanacci V, Nascimbeni R, Dore MP, Pes GM, Maconi G. 2020. Abnormal gut motility in inflammatory bowel disease: an update. Tech Coloproctol. 24(4):275–282. doi: 10.1007/s10151-020-02168-y.
   PubMed Web of Science ®Google Scholar
• Bhagwat A, Pathan IB, Chishti NAH. 2021. Design and optimization of pellet formulations containing curcumin, ascorbic acid, and a co-amorphous mixture for ulcerative colitis management. Part Sci Technol. 39(7):859–867. doi: 10.1080/02726351.2020.1848946.
   Web of Science ®Google Scholar
• Bhatt H, Naik B, Dharamsi A. 2014. Solubility enhancement of budesonide and statistical optimization of coating variables for targeted drug delivery. J Pharm . 2014:262194–262113. doi: 10.1155/2014/262194.
   Google Scholar
• Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A. 2012. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis. 6(4):476–482. doi: 10.1016/j.crohns.2011.10.006.
   PubMed Web of Science ®Google Scholar
• Bruscoli S, Febo M, Riccardi C, Migliorati G. 2021. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Front Immunol. 12:691480. doi: 10.3389/fimmu.2021.691480.
   PubMed Web of Science ®Google Scholar
• Brusini R, Varna M, Couvreur P. 2020. Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Deliv Rev. 157:161–178. doi: 10.1016/j.addr.2020.07.010.
   PubMed Web of Science ®Google Scholar
• Chao L, Zheng P, Xia L, Yong Y, Lu G, Tang F, Zhao Z. 2017. Calycosin attenuates dextran sulfate sodium (DSS)-induced experimental colitis. Iran J Basic Med Sci. 20(9):1056.
   PubMed Web of Science ®Google Scholar
• Chen M, Yu Y, Yang S, Yang D. 2021. Pretreatment with licochalcone enhances the therapeutic activity of rat bone marrow mesenchymal stem cells in animal models of colitis. Iran J Basic Med Sci. 24(8):1050.
   PubMed Web of Science ®Google Scholar
• Cohen R. 2006. Evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 24(3):465–474. doi: 10.1111/j.1365-2036.2006.03010.x.
   PubMed Web of Science ®Google Scholar
• Cohen R, Weisshof R. 2020. A comprehensive review of topical therapies for distal ulcerative colitis. Gastroenterol Hepatol. 16(1):21–27.
   Google Scholar
• Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, Donnelly MC, Wahlich JC, Humphreys JI, Robinson JR, et al. 2019. Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys. Drug Dev Ind Pharm. 45(3):387–394. doi: 10.1080/03639045.2018.1542708.
   PubMed Web of Science ®Google Scholar
• Desai N, Momin M. 2020. Colon targeted bioadhesive pellets of curcumin and cyclosporine for improved management of inflammatory bowel disease. Drug Deliv Transl Res. 10(5):1288–1301. doi: 10.1007/s13346-020-00756-x.
   PubMed Web of Science ®Google Scholar
• Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. 2021. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol. 15(9):1091–1096. doi: 10.1080/17474124.2021.1898944.
   PubMed Web of Science ®Google Scholar
• Foppoli A, Maroni A, Moutaharrik S, Melocchi A, Zema L, Palugan L, Cerea M, Gazzaniga A. 2019. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. Int J Pharm. 572:118723. doi: 10.1016/j.ijpharm.2019.118723.
   PubMedGoogle Scholar
• Franco P, De Marco I. 2020. Eudragit: a novel carrier for controlled drug delivery in supercritical antisolvent coprecipitation. Polymers. 12(1):234–250. doi: 10.3390/polym12010234.
   PubMed Web of Science ®Google Scholar
• Gareb B, Dijkstra G, Kosterink JG, Frijlink HW. 2019. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. Int J Pharm. 554:366–375. doi: 10.1016/j.ijpharm.2018.11.019.
   PubMedGoogle Scholar
• Gareb B, Eissens AC, Kosterink JG, Frijlink HW. 2016. The development of a zero-order sustained-release tablet containing mesalazine and budesonide is intended to treat the distal gastrointestinal tract in inflammatory bowel disease. Eur J Pharm Biopharm. 103:32–42. doi: 10.1016/j.ejpb.2016.03.018.
   PubMed Web of Science ®Google Scholar
• Ghebre-Sellassie I. 1989. Pharmaceutical Pelletization Technology (1st ed.). CRC Press. doi: 10.1201/9781003066231.
   Google Scholar
• Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL. 2018. Budesonide with multi-matrix technology as a second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ. 21(9):869–877. doi: 10.1080/13696998.2018.1484371.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez ML, Maestrelli F, Mura P, Rabasco AM. 2003. In vitro release of sodium diclofenac from a central core matrix tablet aimed at colonic drug delivery. Eur J Pharm Sci. 20(1):125–131. doi: 10.1016/s0928-0987(03)00181-7.
   PubMed Web of Science ®Google Scholar
• Gros B, Kaplan GG. 2023. Ulcerative colitis in adults: a review. Jama. 330(10):951–965. doi: 10.1001/jama.2023.15389.
   PubMed Web of Science ®Google Scholar
• Ganguly D, Choudhury A, Majumdar S. 2023. Nanotechnology approaches for colon targeted drug delivery system: a review. J Young Pharm. 15(2):233–238. doi: 10.5530/jyp.2023.15.32.
   Web of Science ®Google Scholar
• Gupta VK, Beckert TE, Price JC. 2001. A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm. 213(1–2):83–91. doi: 10.1016/s0378-5173(00)00649-9.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S et al. 2017. Third European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current Management. J Crohns Colitis. 11(7):769–784. doi: 10.1093/ecco-jcc/jjx009.
   PubMed Web of Science ®Google Scholar
• Hassan SM, Hassan AH. 2018. The possibility of using shogaol for treatment of ulcerative colitis. Iran J Basic Med Sci. 21(9):943–949.
   PubMed Web of Science ®Google Scholar
• Hussain MS, Mohit KG, Pamma P. 2021. Overview of controlled drug delivery system. Adv Biores. 12(3):248–255.
   Google Scholar
• Ilhan ZE, Marcus AK, Kang D-W, Rittmann BE, Krajmalnik-Brown R. 2017. pH-mediated microbial and metabolic interactions in fecal enrichment cultures. Msphere. 2(3):e00047–00017. doi: 10.1128/mSphere.00047-17.
   Web of Science ®Google Scholar
• Jain K, Sood S, Gowthamarajan K. 2015. Optimization of artemether-loaded NLC for intranasal delivery using a central composite design. Drug Deliv. 22(7):940–954. doi: 10.3109/10717544.2014.885999.
   PubMed Web of Science ®Google Scholar
• Kao C-C, Chen S-C, Sheu M-T. 1997. Lag-time method to delay drug release to various sites in the gastrointestinal tract. J Controlled Release. 44(2–3):263–270. doi: 10.1016/S0168-3659(96)01529-5.
   Web of Science ®Google Scholar
• Kaur K, Kim K. 2009. Studies of a chitosan/organic acid/Eudragit® RS/RL-coated system for colonic delivery. Int J Pharm. 366(1–2):140–148. doi: 10.1016/j.ijpharm.2008.09.006.
   PubMedGoogle Scholar
• Kayal M, Shah S. 2019. Ulcerative colitis: current and emerging treatment strategies. J Clin Med. 9(1):94–106. doi: 10.3390/jcm9010094.
   PubMed Web of Science ®Google Scholar
• Lee SH, Bajracharya R, Min JY, Han J-W, Park BJ, Han H-K. 2020. Strategic approaches for colon-targeted drug delivery: an overview of recent advancements. Pharmaceutics. 12(1):68–88. doi: 10.3390/pharmaceutics12010068.
   PubMed Web of Science ®Google Scholar
• Lin C, Ng HLH, Pan W, Chen H, Zhang G, Bian Z, Lu A, Yang Z. 2015. Exploring different strategies for efficient delivery of colorectal cancer therapy. Int J Mol Sci. 16(11):26936–26952. doi: 10.3390/ijms161125995.
   PubMed Web of Science ®Google Scholar
• Maroni A, Moutaharrik S, Zema L, Gazzaniga A. 2017. Enteric coatings for colonic drug delivery: state of the art. Expert Opin Drug Deliv. 14(9):1027–1029. doi: 10.1080/17425247.2017.1360864.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Basit AW, Murdan S. 2008. Measurements of rat and mouse gastrointestinal pH, fluid, and lymphoid tissue, and implications for in vivo experiments. J Pharm Pharmacol. 60(1):63–70. doi: 10.1211/jpp.60.1.0008.
   PubMed Web of Science ®Google Scholar
• Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S, Lee J, Moon HR, Kim M-S, Jung Y, et al. 2015. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther. 9:3789–3799. doi: 10.2147/DDDT.S88672.
   PubMed Web of Science ®Google Scholar
• Navarro-Ruíz E, Álvarez-Álvarez C, Peña M, Torrado-Salmerón C, Dahma Z, de la Torre-Iglesias PM. 2022. Multiparticulate systems of meloxicam for colonic administration in cancer or autoimmune diseases. Pharmaceutics. 14(7):1504–1522. doi: 10.3390/pharmaceutics14071504.
   PubMed Web of Science ®Google Scholar
• Nerella NG, Block LH, Noonan PK. 1993. The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model. Pharm Res. 10(7):1031–1036. doi: 10.1023/a:1018970924508.
   PubMed Web of Science ®Google Scholar
• Nguyen MN, Tran PH, Tran TT. 2019. A single-layer film coating for colon-targeted oral delivery. Int J Pharm. 559:402–409. doi: 10.1016/j.ijpharm.2019.01.066.
   PubMedGoogle Scholar
• Nie X, Wang B, Hu R, Lu W, Chen J, Liu S, Jin D, Sun C, Gao S, Guo Y, et al. 2020. Development and evaluation of controlled and simultaneous release of compound Danshen based on a novel colon-specific osmotic pump capsule. Aaps Pharmscitech. 21(2):38. doi: 10.1208/s12249-019-1603-9.
   PubMed Web of Science ®Google Scholar
• Nugent S, Kumar D, Rampton D, Evans D. 2001. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 48(4):571–577. doi: 10.1136/gut.48.4.571.
   PubMed Web of Science ®Google Scholar
• Ofokansi KC, Kenechukwu FC. 2013. Formulation development and evaluation of drug release kinetics from colon-targeted ibuprofen tablets based on Eudragit RL 100-chitosan interpolyelectrolyte complexes. Int Scholarly Res Not. 2013:1–8.
   Google Scholar
• Ozturk A, Ozturk SS, Palsson B, Wheatley T, Dressman JB. 1990. Mechanism of release from pellets coated with an ethylcellulose-based film. J Controlled Release. 14(3):203–213. doi: 10.1016/0168-3659(90)90160-U.
   Web of Science ®Google Scholar
• Park HJ, Jung HJ, Ho MJ, Lee DR, Cho HR, Choi YS, Jun J, Son M, Kang MJ. 2017. Colon-targeted delivery of solubilized bisacodyl by a doubly enteric-coated multiple-unit tablet. Eur J Pharm Sci. 102:172–179. doi: 10.1016/j.ejps.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Patel MM. 2011. Cutting-edge technologies in colon-targeted drug delivery systems. Expert Opin Drug Deliv. 8(10):1247–1258. doi: 10.1517/17425247.2011.597739.
   PubMed Web of Science ®Google Scholar
• Patel J, Patel K, Shah S. 2023. Fabrication of a dual-triggered natural gum–based multi-particulate colon-targeted drug delivery system of budesonide using the QbD Approach. J Pharm Innov. 18(4):1992–2012. doi: 10.1007/s12247-023-09764-z.
   Web of Science ®Google Scholar
• Patel NV, Patel JK, Shah SH, Patel JN. 2011. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis. Die Pharmazie. Int J Pharm Sci. 66(2):124–129.
   Google Scholar
• Raval MK, Ramani RV, Sheth NR. 2013. Formulation and evaluation of sustained-release enteric-coated pellets of budesonide for intestinal delivery. Int J Pharm Investig. 3(4):203–211. doi: 10.4103/2230-973X.121294.
   PubMedGoogle Scholar
• Rojo E, Casanova MJ, Gisbert JP. 2020. Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients. Revista Espanola de Enfermadades Digestivas. 112(1):53–59.
   PubMed Web of Science ®Google Scholar
• Ruban M, Slavick A, Amir A, Ben-Tov A, Moran-Lev H, Weintraub Y, Anafy A, Cohen S, Yerushalmy-Feler A. 2022. Increasing rates of a positive family history of inflammatory bowel disease (IBD) in pediatric IBD patients. Eur J Pediatr. 181(2):745–751. doi: 10.1007/s00431-021-04269-8.
   PubMed Web of Science ®Google Scholar
• Sangnim T, Tangpanithanon A, Khamtheantong M, Charoenwai J, Huanbutta K. 2021. Development of personalized colonic drug delivery systems prepared by 3D-printing technology. KEM. 901:144–150. doi: 10.4028/www.scientific.net/KEM.901.144.
   Google Scholar
• Sardou HS, Akhgari A, Mohammadpour AH, Kamali H, Jafarian AH, Garekani HA, Sadeghi F. 2021. Application of inulin/Eudragit RS in 5-ASA pellet coating with a tuned, sustained-release feature in an animal model of ulcerative colitis. Int J Pharm. 597:120347. doi: 10.1016/j.ijpharm.2021.120347.
   PubMedGoogle Scholar
• Sardou HS, Akhgari A, Mohammadpour AH, Namdar AB, Kamali H, Jafarian AH, Garekani HA, Sadeghi F. 2022. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon-targeted delivery of 5-ASA pellets in rats with ulcerative colitis. Eur J Pharm Sci. 168:106072. doi: 10.1016/j.ejps.2021.106072.
   PubMed Web of Science ®Google Scholar
• Segal PJ, LeBlanc JF, Hart AL. 2021. Ulcerative colitis: an update. Clin Med. 21(2):135–139. doi: 10.7861/clinmed.2021-0080.
   PubMed Web of Science ®Google Scholar
• Singh A, Mandal UK, Narang RK. 2021. Development and characterization of enteric-coated pectin pellets containing mesalamine and Saccharomyces Boulardii for specific inflamed colons: in vitro and in vivo evaluation. J Drug Delivery Sci Technol. 62:102393. doi: 10.1016/j.jddst.2021.102393.
   Web of Science ®Google Scholar
• Soltani F, Kamali H, Akhgari A, Garekani HA, Nokhodchi A, Sadeghi F. 2022. There are different trends for the preparation of budesonide pellets with enhanced dissolution rates. Adv Powder Technol. 33(8):103684. doi: 10.1016/j.apt.2022.103684.
   Web of Science ®Google Scholar
• Soltani F, Kamali H, Akhgari A, Rahbardar MG, Garekani HA, Nokhodchi A, Sadeghi F. 2023. Combination of time-dependent polymer and inulin as a coating for sustained delivery of budesonide pellets aimed for use in IBD treatment. J Drug Delivery Sci Technol. 88:104927. doi: 10.1016/j.jddst.2023.104927.
   Web of Science ®Google Scholar
• Vani GS, Kiranmai C, Latha BH, Padmalatha K. 2023. A review on osmotic drug delivery system. Asian J Pharm Techno. 13(1):70–76.
   Google Scholar
• Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Rahmani N, Dorkoosh F, Mahzouni P. 2011. Development of novel budesonide pellets based on CODESTM technology: in vitro/in vivo evaluation in induced colitis in rats. Daru: J Facul Pharm, Tehran Univ Med Sci. 19(2):107–117.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Rahmani N, Dorkoosh F, Mahzouni P. 2012. Colon-specific delivery of budesonide based on triple-coated pellets: in vitro and in vivo evaluation. Acta Pharm. 62(3):341–356. doi: 10.2478/v10007-012-0025-y.
   PubMed Web of Science ®Google Scholar
• Vemula SK, Daravath B, Gummadi SB, Repka M. 2023. Formulation and development of flurbiprofen colon-specific eudragit coated matrix tablets: use of a novel crude banana peel powder as a time-dependent polymer. AAPS PharmSci Tech. 24(7):189.
   PubMed Web of Science ®Google Scholar
• Wang P, Luo Q, Miao Y, Ying L, He H, Cai C, Tang X. 2012. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Drug Dev Ind Pharm. 38(11):1344–1353. doi: 10.3109/03639045.2011.650647.
   PubMed Web of Science ®Google Scholar
• Yan Y, Ren F, Wang P, Sun Y, Xing J. 2019. Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis. Iran J Basic Med Sci. 22(12):1452–1461.
   PubMed Web of Science ®Google Scholar